Established in 2018, AcornMed Biotechnology Co., Ltd. (AcornMed) is headquartered in Beijing with four wholly-owned subsidiaries in Tianjin and Qingdao. Leveraging our exclusive Biomarker discovery platform, AcornMed focuses on addressing unmet clinical needs, and continuously develops first-in-class products with original innovation, aiming to become a world-leading company in precision oncology.

We have structured our business into three major business segments: early screening, diagnosis and monitoring of cancer, medical testing for cancer patients and collaborative research and development with global anti-tumor pharmaceutical companies.